NCT06836726View on ClinicalTrials.gov

Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2029

Conditions
Castration Resistant Prostate Cancer
Interventions
DRUG

Evofosfamide

This study is evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs.

Trial Locations (1)

M7A 2S4

Princess Margaret Cancer Center, Toronto

Sponsors

Collaborators (1)

ImmunoGenesis
All Listed Sponsors
collaborator

ImmunoGenesis

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT06836726 - Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter